Provided by Tiger Fintech (Singapore) Pte. Ltd.

Century Therapeutics, Inc.

0.5963
+0.03786.77%
Post-market: 0.5753-0.0210-3.52%19:31 EDT
Volume:472.58K
Turnover:280.44K
Market Cap:50.70M
PE:-0.33
High:0.6284
Open:0.5575
Low:0.5506
Close:0.5585
Loading ...

BRIEF-Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency

Reuters
·
01 Mar

Leerink Partners Remains a Buy on Century Therapeutics (IPSC)

TIPRANKS
·
14 Feb

Century announces investigator-initiated Phase 1/2 trial of CNTY-101

TIPRANKS
·
21 Jan

Century Therapeutics- Enters Investigator-Initiated Phase 1/2 Trial of Ipsc-Derived Ink Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases

THOMSON REUTERS
·
21 Jan

Century Therapeutics Inc: Caramel Trial With Century Is Intended to Commence in Mid-2025 Following Cta Approval

THOMSON REUTERS
·
21 Jan

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

GlobeNewswire
·
21 Jan

Cautious Optimism on Century Therapeutics: Promising Early-Stage Developments But Awaiting Further Data

TIPRANKS
·
14 Jan

Piper Sandler Adjusts Price Target on Century Therapeutics to $4 From $12, Keeps Overweight Rating

MT Newswires Live
·
31 Dec 2024

Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)

TIPRANKS
·
30 Dec 2024

Century Therapeutics price target lowered to $4 from $12 at Piper Sandler

TIPRANKS
·
30 Dec 2024

Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)

TIPRANKS
·
18 Dec 2024

Century Therapeutics Faces Termination of BMS Agreement

TIPRANKS
·
14 Dec 2024

Century Therapeutics - Termination Effective March 12, 2025

THOMSON REUTERS
·
14 Dec 2024

Century Therapeutics - to Evaluate Opportunities in Aml and Multiple Myeloma

THOMSON REUTERS
·
14 Dec 2024

Century Therapeutics- Bms Notified Co on Dec 12 to Terminate Collaboration Agreement With Century Therapeutics

THOMSON REUTERS
·
14 Dec 2024

Leerink Partners Reaffirms Their Buy Rating on Century Therapeutics (IPSC)

TIPRANKS
·
27 Nov 2024